Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02347449

The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population

Hormone Receptor Positive Malignant Neoplasm of Breast Clinical Trial

Official title:
The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population of Patients With Estrogen Receptor- Positive Early Breast Cancer With 1-3 Positive Lymph Nodes

Clinical Trial Summary

The main goal of this study is to characterize whether the results of the Oncotype DX® assay affect the physician's treatment recommendations for the adjuvant treatment of women with ER-positive (ER+), early breast cancer (EBC) with 1-3 positive lymph nodes who are potential candidates for chemotherapy, but for whom the benefits of chemotherapy may be uncertain.

Clinical Trial Description

The Oncotype DX assay has been commercially available in the U.S. since 2004 as a tool to aid a physician's treatment recommendation for a breast cancer patient. While the Oncotype DX assay is currently reimbursed by the Ontario Health Ministry for node-negative EBC, it is not reimbursed for node-positive (N+) patients although the assay has been shown to be both prognostic and predictive of chemotherapy benefit for patients with N+ disease. The goal of this study is to characterize how the results of the Oncotype DX® assay impact the decision making processes of physicians and patients in a large academic medical center in Ontario by evaluating recommendations for adjuvant therapy within a population of ER+, N+ EBC patients with 1 to 3 positive lymph nodes for whom the benefit of adjuvant chemotherapy is not certain. Upon consent, the patient will be assigned an ID number. The physician will discuss the patient's treatment alternatives prior to ordering the Oncotype DX assay. After discussion with the patient, the physician will complete a baseline questionnaire indicating the therapeutic strategy he/she would recommend to the patient based upon the available clinical and pathologic data. In addition, the patient will also complete a baseline questionnaire indicating her treatment preference, based on the previous discussion with the physician. The Oncotype DX assay will be ordered after receipt of the Registration and Confirmation of Eligibility Form and assignment of patient study number. Once the results of the Oncotype DX assay are available, the physician will discuss the results with the patient. Both the physician and the patient will complete separate follow-up post-assay questionnaires after the results of the Oncotype DX assay are known and shared with the patient. One last form completed by a study manager or coordinator after a treatment plan has been initiated will register the actual treatment administered to the patient. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02347449
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact
Status Completed
Phase N/A
Start date October 2014
Completion date September 30, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03165487 - Comparison of the Breast Tumor Microenvironment
Completed NCT03088527 - Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer Phase 1
Withdrawn NCT04088032 - Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer Early Phase 1
Completed NCT04483505 - Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. Phase 1
Not yet recruiting NCT04088110 - Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer Phase 2
Completed NCT01617954 - PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score N/A
Completed NCT01589367 - Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Phase 2
Active, not recruiting NCT02109913 - Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane N/A
Active, not recruiting NCT02668666 - Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Not yet recruiting NCT03910712 - Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC Phase 2
Recruiting NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer N/A
Completed NCT03969121 - Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer Phase 3
Recruiting NCT06120283 - BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors Phase 1
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4
Completed NCT03594578 - Prospective Thinking in Hormone-Responsive Breast Cancer N/A
Recruiting NCT06253195 - BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors Phase 1
Not yet recruiting NCT02025712 - Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer Phase 2